Hygiene EducationHealth Education
Vinorelbine is a member of the vinca alkaloids derived from the periwinkle plant. This medicine binds to the tubulin and inhibits microtubule assembly, thus stopping a cell from separating into two new cells, eventually causing cell death. This cell damage slows or stops the growth of cancer cells in the body.
Idarubicin is classified as an anthracyline anticancer antibiotic. This drug inhibits DNA synthesis by producing DNA cross-links which halt cell replication and eventually causing cell death.
Aldesleukin is a synthetic interleukin-2 that stimulates the immune system by encouraging the growth of certain white blood cells called T lymphocytes and natural killer cells in the body. This helps the body fight cancers.
Capcitabine is classified as an anticancer antimetabolites. This medicine inhibits thymidylate synthase that is essential for the formation of DNA and RNA. This stops the growth of cancer cells, causing the cancer cells to die.
G-CSF is a growth factor that stimulates the bone marrow to produce more blood cells.
UFT is classified as anticancer antimetabolites. UFT is made up of two drugs that are combined together: tegafur and uracil. This medicine inhibits thymidylate synthase that is essential for the formation of DNA and RNA. This stops the growth of cancer cells, causing the cancer cells to die.
Roferon-A® is a synthetic interferon alfa-2a that stimulates T cells and other immune system cells to fight certain types of cancer.
Lipo-Dox® is doxorubicin covered in tiny spheres called liposomes. These spheres keep the doxorubicin in the bloodstream longer and has more time to reach the tumor tissue, thus significantly lowering the side effects.
Oxaliplatin, a platinum compound, is an alkylating agent that exerts its anticancer activity by reacting with DNA and interfering with DNA replication and cell division. This stops the growth and spread of cancer cell in the body.
Rituximab is a monoclonal antibody that targets to a protein called CD20 on the surface of white blood cells known as B lymphocytes. When rituximab sticks to the surface of these cells, the abnormal growth of the B lymphocytes is stopped and triggers cell death.